Citations

Showing 10 of 108119 citations.

BRAF Rearrangements and BRAF V600E Mutations Are Seen in a Subset of Pancreatic Carcinomas With Acinar Differentiation
Ghosh, Toshi, Greipp, Patricia T. , Knutson, Darlene L., Kloft‐Nelson, Sara M. , Jenkins, Sarah M. , Mounajjed, Taofic, Said, Samar M. , Sessa, Fausto , Naini, Bita V. , Zhang, Lizhi , Kerr, Sarah E. , Graham, Rondell P. , Knutson, Darlene, Kloft-Nelson, Sara, Graham, Rondell P , Greipp, Patricia T , Rosa, Stefano La , Vanoli, Alessandro , Bellizzi, Andrew M.

Mayo Clinic

Archives of Pathology & Laboratory Medicine | October 9, 2021 | Volume: 146 | Issue: 7 | Pages: 840-845

10.5858/arpa.2020-0739-oa | PMID 34614142 Get It

Context.— Comprehensive genomic profiling has demonstrated that approximately 20% of pancreatic carcinomas with acinar differentiation harbor potentially targetable BRAF fusions that activate the MAPK pathway. Objectives.— To validate the above finding by BRAF break-apart fluorescence in situ hybridization (FISH) in a large series of pure acinar cell carcinomas (ACCs), evaluate tumors for the presence of BRAF V600E mutations, and compare clinicopathologic features of tumors with BRAF rearrangements with those without. Design.— Thirty cases of pure ACC and 6 cases of mixed acinar-neuroendocrine carcinoma (ACC-NEC) were retrieved. A break-apart FISH probe was used to detect BRAF rearrangements. Immunohistochemistry for BRAF V600E was performed. Results.— BRAF rearrangements by FISH were found in 6 of 36 cases (17%), 5 of which were pure ACC and 1 was a mixed ACC-NEC. Follow-up was available in 29 of 36 cases (81%). The median survival was 22 months for BRAF-rearranged cases and 16 months for BRAF-intact cases; the 2-year overall survival was 50% for BRAF-rearranged cases and 35% for BRAF-intact cases. No significant clinicopathologic differences were identified in cases with BRAF rearrangement compared with those without BRAF rearrangement. BRAF V600E mutation was identified in 2 of 34 cases (6%), both of which were pure ACC and were BRAF-intact by FISH. Conclusions.— This study supports the finding that BRAF rearrangements are present in approximately 20% of cases and identified BRAF V600E mutations in approximately 5% of cases. These cases may benefit from targeted therapy.
Pustular psoriasis flare‐up in a patient with COVID‐19
Miladi, Ronak , Janbakhsh, Alireza , Aryanian, Zeinab , Ebrahimpour, Soheil , Barary, Mohammad , Wollina, Uwe , Afshar, Zeinab Mohseni , Babazadeh, Arefeh , Aryanian, Zeinab , Ebrahimpour, Soheil , Barary, Mohammad , Wollina, Uwe , Goldust, Mohamad , Mohseni Afshar, Zeinab , Sio, Terence T.

Mayo Clinic

Journal of Cosmetic Dermatology | October 9, 2021 | Volume: 20 | Issue: 11 | Pages: 3364-3368

10.1111/jocd.14508 | PMID 34619013 Get It

AbstractIntroductionThe various cutaneous manifestations have lately appeared in the setting of COVID‐19. Psoriasis flare‐ups have been reported during a COVID‐19 infection.Case presentationWe present a case of a 32‐year‐old woman with COVID‐19 who presented with generalized pustular psoriasis. She received oral prednisolone, hydroxyzine, and topical clobetasol. The patient received follow‐up two weeks later and found that her lesions were favorably desquamating.MethodsThe PubMed, SCOPUS, and ISI Web of Science databases were thoroughly searched for English studies reporting psoriasis flare‐ups following SARS‐CoV‐2 infection. Ten case reports/series were included after screening.ConclusionsOur case report brings awareness to clinicians for the possible cutaneous manifestation of COVID‐19, which should be considered part of the differential diagnoses.
Novel Applications of Metagenomics for Detection of Tickborne Pathogens
Rodino, Kyle G. , Pritt, Bobbi S. , Pritt, Bobbi S

Mayo Clinic

Clinical Chemistry | October 9, 2021 | Volume: 68 | Issue: 1 | Pages: 69-74

10.1093/clinchem/hvab228 | PMID 34969117 Get It

Abstract Background Tick populations have expanded in many parts of the globe, bringing with them an enhanced appreciation and discovery of novel tickborne pathogens, as well an increased in reported human cases of tickborne disease. Targeted and unbiased (shotgun) clinical metagenomic sequencing tests are increasingly used for detection of known and emerging infectious agents and have recently been employed for detection of tickborne pathogens. Content This review describes the types of metagenomic sequencing assays used for detection of emerging tickborne pathogens and reviews the recent literature on this topic. Important diagnostic and interpretative challenges are also covered. Summary Metagenomic analysis has emerged as a powerful tool for detection, discovery, characterization, and classification of tickborne pathogens. Shotgun metagenomics is especially promising because it allows for detection of all tickborne bacteria, viruses, and parasites in a single specimen. Despite the potential advantages, there are several important challenges, including high cost, complexity of testing and interpretation, and slow turnaround time. No doubt, these challenges will diminish with increased use and advances in the field.
Antibody incidence and red blood cell transfusions in patients on daratumumab
Tauscher, Craig D. , Moldenhauer, Sheila K., Bryant, Sandra C. , DiGuardo, Margaret , Jacob, Eapen K., Tauscher, Craig , Moldenhauer, Sheila, Bryant, Sandra

Mayo Clinic

Transfusion | October 9, 2021 | Volume: 61 | Issue: 12 | Pages: 3468-3472

10.1111/trf.16687 | PMID 34617617 Get It

AbstractBackgroundDaratumumab (Dara), an anti‐CD38 monoclonal antibody for hematologic malignancies, interferes with routine blood bank testing, specifically affecting the antibody screen and identification panels. In 2016, the AABB recommended performing a baseline phenotype or genotype before a patient (Pt) begins taking anti‐CD38 to avoid this interference and potential problems with transfusion. The objective of this study was to assess red blood cell (RBC) utilization and subsequent incidence of alloimmunization to the transfused RBCs in patients receiving Dara.Methods and MaterialsWe monitored 244 patients taking Dara to determine their red blood cell transfusions and incidence of clinically significant antibody formation before and following administration of Dara. Poisson generalized estimating equations with log link were used comparing the post‐Dara incidence and prevalence to those prior, with significance defined as p < .05.ResultsFrom September 1, 2015 to December 22, 2018, 244 patients on Dara were identified, of which 145 patients (59.4%) received a red blood cell transfusion. Antibody screens were performed on 97 of the 145 patients at least 2 weeks following RBC transfusion. Four of the total transfused patients (2.8% total, 4.1% patients with follow‐up antibody screen testing) formed new clinically significant alloantibodies, which was not significantly different from Asare's hematologic incidence (p = .98/p = .49).ConclusionsThis study showed our patients on Dara did not form alloantibodies following RBC transfusion at a higher incidence than similar patient populations.
Faecal Calprotectin from Ileostomy Output Is Sensitive and Specific for the Prediction of Small Bowel Inflammation in Patients with Crohn’s Disease
Daoud, Nader , Picco, Michael F., Daoud, Nader D, Hashash, Jana G. , Farraye, Francis A.

Mayo Clinic

Journal of Crohn's and Colitis | October 9, 2021 | Volume: 16 | Issue: 4 | Pages: 601-605

10.1093/ecco-jcc/jjab182 | PMID 34633435 Get It

Abstract Background Severe Crohn’s disease [CD] can result in extensive bowel resections and need for creation of an ileostomy. Faecal calprotectin [FC] is well studied in CD management, though its role in patients who have an ileostomy is unclear. Our aim is to understand if FC is a useful adjunct to radiographic or endoscopic studies in identifying recurrent CD after surgery in patients with an ileostomy. Methods Between January 1, 2017, and September 30, 2020, we searched the Mayo Clinic electronic medical record retrospectively for adult patients with ICD-10 code for CD, and a surgical history of an ileostomy. Patients were included in the analysis if they had at least one FC measured and a concomitant radiographic imaging and/or endoscopic procedure. An abnormal FC was defined as greater than 60 µg/g. Results Of 51 patients who met our inclusion criteria, 17 had an FC level &gt;60 µg/g. Of these 17 patients, 14 had imaging and/or an ileoscopy confirming the presence of small bowel inflammation, with a sensitivity of 87.5%. Of the remaining 34 patients with an FC level ≤60 µg/g, 32 patients had imaging and/or ileoscopy demonstrating no small bowel inflammation, with a specificity of 91.4%. FC from an ileostomy effluent had a positive predictive value of 82.3%, a negative predictive value of 94.1% and test diagnostic accuracy of 90.1%. Conclusion FC from an ileostomy effluent is a highly sensitive and specific test for the assessment and monitoring of small bowel inflammation and disease recurrence in patients with CD.
Mendelian Randomisation Study of Smoking, Alcohol, and Coffee Drinking in Relation to Parkinson’s Disease
Domenighetti, Cloé , Sreelatha, Ashwin Ashok Kumar , Grover, Sandeep , Mohamed, Océane, Portugal, Berta , May, Patrick , Bobbili, Dheeraj Reddy , Radivojkov‐Blagojevic, Milena , Lichtner, Peter , Singleton, Andrew , Hernandez, Dena G., Edsall, Connor , Mellick, George D. , Zimprich, Alexander , Pirker, Walter , Kõks, Sulev, Lesage, Suzanne , Chartier‐Harlin, Marie‐Christine , Brockmann, Kathrin , Deutschländer, Angela , Hadjigeorgiou, G., Dardiotis, Efthimos, Simitsi, Athina Maria, Petrucci, Simona , Straniero, Letizia , Pezzoli, Gianni , Brighina, Laura , Ferrarese, Carlo , Annesi, Grazia , Quattrone, Andrea , Kawamura, Yusuke , Hattori, Nobutaka , Kim, Yun Joong , Kolber, Pierre, Warrenburg, Bart P. van de, Bloem, Bastiaan R. , Aasly, Jan , Toft, Mathias , Ferreira, Joaquim J. , Bardien, Soraya , Tolosa, Eduardo , Ezquerra, Mario , Pástor, Pau , Wirdefeldt, Karin , Ran, Caroline , Puschmann, Andreas , Hellberg, Clara , Clarke, Carl E , Morrison, Karen , Krainc, Dimitri , Burbulla, Lena F. , Krüger, Rejko , Gasser, Thomas , Sharma, Manu , Elbaz, Alexis , Deutschländer, Angela B., Puschmann, Andreas , Bardien, Soraya , Bobbili, Dheeraj R , Toft, Mathias , Ezquerra, Mario , Elbaz, Alexis , Grover, Sandeep , May, Patrick , Ferreira, Joaquim J , Zimprich, Alexander , Pastor, Pau , Koks, Sulev , Sugier, Pierre‐Emmanuel , Schulte, Claudia , Rogaeva, Ekaterina A. , Lang, Anthony E. , Taba, Pille , Brice, Alexis , Corvol, Jean‐Christophe , Mutez, Eugénie , Stefanis, Leonidas , Simitsi, Athina‐Maria , Valente, Enza Maria , Duga, Stefano , Zecchinelli, Anna , Gagliardi, Monica , Matsuo, Hirotaka , Nishioka, Kenya , Chung, Sun Ju , Pihlstrøm, Lasse , Guedes, Leonor Correia , Carr, Jonathan , Díez-Fairén, Mónica , Pedersen, Nancy L. , Belin, Andrea Carmine , Tan, Manuela , Farrer, Matthew J. , Domenighetti, Cloé

Mayo Clinic

Journal of Parkinson's Disease | October 9, 2021 | Volume: 12 | Issue: 1 | Pages: 267-282

10.3233/jpd-212851 | PMID 34633332 Get It

Background: Previous studies showed that lifestyle behaviors (cigarette smoking, alcohol, coffee) are inversely associated with Parkinson’s disease (PD). The prodromal phase of PD raises the possibility that these associations may be explained by reverse causation. Objective: To examine associations of lifestyle behaviors with PD using two-sample Mendelian randomisation (MR) and the potential for survival and incidence-prevalence biases. Methods: We used summary statistics from publicly available studies to estimate the association of genetic polymorphisms with lifestyle behaviors, and from Courage-PD (7,369 cases, 7,018 controls; European ancestry) to estimate the association of these variants with PD. We used the inverse-variance weighted method to compute odds ratios (ORIVW) of PD and 95%confidence intervals (CI). Significance was determined using a Bonferroni-corrected significance threshold (p = 0.017). Results: We found a significant inverse association between smoking initiation and PD (ORIVW per 1-SD increase in the prevalence of ever smoking = 0.74, 95%CI = 0.60–0.93, p = 0.009) without significant directional pleiotropy. Associations in participants ≤67 years old and cases with disease duration ≤7 years were of a similar size. No significant associations were observed for alcohol and coffee drinking. In reverse MR, genetic liability toward PD was not associated with smoking or coffee drinking but was positively associated with alcohol drinking. Conclusion: Our findings are in favor of an inverse association between smoking and PD that is not explained by reverse causation, confounding, and survival or incidence-prevalence biases. Genetic liability toward PD was positively associated with alcohol drinking. Conclusions on the association of alcohol and coffee drinking with PD are hampered by insufficient statistical power.
Systematic Review and Meta-Analysis of Cisplatin Based Neoadjuvant Chemotherapy in Muscle Invasive Bladder Cancer
Benkhadra, Raed, Nayfeh, Tarek , Patibandla, Sai Krishna, Peterson, Chelsea , Mao, Shifeng , Nayfeh, Tarek , Peterson, Chelsea , Prokop, Larry J. , Alhalabi, Omar , Murad, M. Hassan

Mayo Clinic

Bladder Cancer | October 8, 2021 | Volume: 8 | Issue: 1 | Pages: 5-17

10.3233/blc-201511 | PMID 38994516 Get It

BACKGROUND: Cisplatin-based neoadjuvant chemotherapy is the standard of care for muscle invasive bladder cancer (MIBC). OBJECTIVE: To compare the efficacy and safety of the two most commonly used cisplatin-based regimens; gemcitabine, and cisplatin (GC) vs. accelerated (dose-dense: dd) or conventional methotrexate, vinblastine, adriamycin, and cisplatin (MVAC). METHODS: We searched MEDLINE, Embase, Scopus and other sources. Outcomes of interest included overall survival, downstaging to pT≤1, pathologic complete response (pCR), recurrence, and toxicity. Meta-analysis was conducted using the random-effects model. RESULTS: We identified 24 studies. Efficacy outcomes were comparable between MVAC and GC for MIBC. dd-MVAC was associated with favorable efficacy compared to GC in terms of downstaging (OR 1.45; 95%CI 1.15–1.82) and all-cause mortality at longest follow-up (OR 0.63; 95%CI 0.44–0.81). However, GC was associated with a better safety profile in terms of febrile neutropenia (OR 0.32; 95%CI 0.13–0.80), anemia (OR 0.32; 95%CI 0.18–0.54), nausea and vomiting (OR 0.27; 95%CI 0.12–0.65) compared to dd-MVAC. Compared to MVAC, patients receiving GC had an increased risk of developing grade 3–4 thrombocytopenia (OR 4.70; 95%CI 1.59–13.89) and a lower risk of nausea and vomiting (OR 0.05; 95%CI 0.01–0.31). Certainty in the estimates was very low for most outcomes. CONCLUSIONS: Efficacy and safety outcomes were comparable between MVAC and GC for MIBC. Including non-peer-reviewed studies showed higher efficacy with dd-MVAC. A phase III randomized trial comparing the two regimens is needed to guide clinical practice.
Commentary: Endoscopic Endonasal Versus Transoral Odontoidectomy for Non-Neoplastic Craniovertebral Junction Disease: A Case Series
Yagnik, Karan J. , Peris‐Celda, Maria , Pinheiro-Neto, Carlos D., Pinheiro‐Neto, Carlos

Mayo Clinic

Operative Neurosurgery | October 8, 2021 | Volume: 21 | Issue: 6 | Pages: E465-E466

10.1093/ons/opab352 | PMID 34624884 Get It

A comparison of 9‐min colonoscopy withdrawal time and 6‐min colonoscopy withdrawal time: A systematic review and meta‐analysis
Bhurwal, Abhishek , Rattan, Puru , Sarkar, Avik , Haroon, Shahid, Gjeorgjievski, Mihajlo , Bansal, Vikas , Mutneja, Hemant , Bansal, Vikas , Patel, Anish V. , Mutneja, Hemant

Mayo Clinic

Journal of Gastroenterology and Hepatology | October 8, 2021 | Volume: 36 | Issue: 12 | Pages: 3260-3267

10.1111/jgh.15701 | PMID 34617312 Get It

AbstractIntroductionThe optimal colonoscopy withdrawal time is still a controversial topic. While several studies demonstrate that longer withdrawal time improves adenoma detection rate, others have contradicted these findings.MethodsThree independent reviewers performed a comprehensive review of all original articles published from inception to January 2021 and included studies reporting comparison of the two cohorts—(i) ≥ 6 but less than 9 min of colonoscopy withdrawal time (CWT) and (ii) ≥ 9 min of CWT. The outcome measures were the following: (i) adenoma detection rate (ADR), (ii) advanced ADR, and (iii) sessile serrated adenoma detection rate (SDR). The meta‐analysis was performed, and the statistics were two‐tailed.ResultsA total of seven studies met the inclusion criteria after a thorough search of the literature was completed. The analysis revealed that ≥ 9 min of CWT had significantly higher odds of adenoma detection as compared with 6–9 min of CWT (odds ratio [OR] 1.54, 95% confidence interval [CI] 1.30–1.82; I2 = 93.7). Additionally, a significantly higher odds of sessile serrated adenoma detection (OR 1.68, 95% CI 1.28–2.22; I2 = 0) and a trend towards higher odds of advanced adenoma detection (OR 1.38, 95% CI 0.98–1.95, I2 = 90) were seen with CWT of at least 9 min when compared with 6–9 min of CWT.ConclusionThis systematic review and meta‐analysis analysis provides further evidence that at least 9 min of CWT cohort had significantly higher ADR and SDR as compared with the at least 6 min but less than 9 min of cohort.
Immune‐mediated necrotizing myopathy: Unusual presentations of a treatable disease
Nicolau, Stefan , Milone, Margherita , Tracy, Jennifer A., Mills, John R. , Triplett, James , Liewluck, Teerin , Triplett, James D, Liewluck, T , Nicolau, Stefan , Triplett, James D

Mayo Clinic

Muscle & Nerve | October 8, 2021 | Volume: 64 | Issue: 6 | Pages: 734-739

10.1002/mus.27435 | PMID 34617293 Get It

AbstractIntroduction/AimsImmune‐mediated necrotizing myopathy (IMNM) is an immune‐mediated myopathy typically presenting with progressive subacute weakness and characteristic, but nonspecific, myopathological findings. Atypical cases however can mimic other inherited or acquired myopathies, depriving patients of treatment. We describe a cohort of such patients.MethodsWe retrospectively identified IMNM patients who either previously carried a diagnosis of an inherited myopathy established on clinicopathological grounds or whose muscle biopsies displayed atypical features suggestive of a different myopathy.ResultsAmong 131 IMNM patients, seven previously unreported patients (5%) met one of the above criteria. Three patients were diagnosed with limb‐girdle muscular dystrophy on the basis of a chronic progressive course of weakness and family history of myopathy or cardiomyopathy. The other four patients displayed atypical histological features (two prominent mitochondrial abnormalities, one myofibrillar pathology, and one granulomatous inflammation). Immunostaining of biopsies from 12 additional IMNM patients did not identify myofibrillar pathology. The patient with granulomatous inflammation was known to have pulmonary sarcoidosis. Genetic testing for inherited myopathies was unrevealing. Antibodies against 3‐hydroxy‐3‐methylglutaryl‐CoA reductase or signal recognition particle were identified in 5 and 1 patients, respectively. Four patients presented with slowly progressive weakness over 3–13 y, while weakness was subacute over ≤6 mo in three patients. All patients responded to immunomodulatory therapy.DiscussionAtypical clinical and histological features can occur in IMNM patients, causing delays in diagnosis and treatment. Clinicians should, therefore, consider IMNM in the differential diagnosis of unexplained proximal myopathies in spite of atypical clinical and myopathological findings.